New breakthrough in research on umbilical cord mesenchymal stem cells for the treatment of pulmonary bronchial dysplasia! Dr. Liao Yan’s team from Beike Biological R&D Center published the latest paper


Beike Biological R&D Team
Carry out in cooperation with many medical institutions in Shenzhen
Umbilical cord mesenchymal stem cells in the treatment of pulmonary bronchial dysplasia
Phase results have been achieved and will
The research results were published in SCI journals
“Frontiers in Cell and Developmental Biology”
Thesis impact factor is 6.68 points
Mesenchymal stem cells VS pulmonary bronchial dysplasia
Bronchopulmonary dysplasia (BPD, Bronchopulmonary dysplasia) is the most common respiratory disease in premature infants and one of the important causes of neonatal death[1]. The existing treatments for BPD are mainly comprehensive prevention and treatment, including improving pulmonary surfactant, lung protective ventilation to assist breathing, caffeine citrate, etc. However, the prognostic indicators of BPD have not been effectively improved under existing treatment methods, and the incidence has increased. Currently, there is no unified and effective drug for the clinical treatment of BPD, so it is urgent to find new treatment strategies to improve this serious and refractory disease.

Inflammatory damage is the main cause of pulmonary bronchial dysplasia in newborns, originating from umbilical cord tissueMesenchymal stem cells (MSCs) have become the preferred stem cell type for the treatment of inflammatory injury diseases due to their low immunogenicity and strong immunosuppressive ability, and also bring hope to the treatment of bronchial dysplasia. Currently, there are many reports at home and abroad about the effectiveness of MSCs in improving lung injury related to premature infants.

Mesenchymal stem cells treat pulmonary bronchial dysplasia, and obtaining sufficient MSCs through in vitro expansion is a prerequisite for clinical treatment. In past preclinical and clinical studies for the treatment of BPD, most of them used fetal bovine serum (FBS) as a culture additive for human MSCs[2]. But this is no longer in line with the latest requirements for human-derived stem cell products from the Center for Drug Evaluation of the National Medical Products Administration (NMPA) – “The use of animal-derived materials should be avoided as much as possible in the production of stem cell products.” At the same time, fetal bovine serum is a heterologous protein, and culturing and expanding human MSCs will increase their immunogenicity and promote cell senescence [3]. Therefore, efforts are being made worldwide to find alternatives to fetal bovine serum. Currently, a commercialized human platelet lysate (hPL) has received great attention from scientific researchers as an additive for mesenchymal stem cell culture.

Beike Biotech published the latest paper in cooperation with many medical institutions in Shenzhen

The research was jointly carried out by Dr. Liao Yan’s team at Beike Biotechnology R&D Center and Shenzhen Longgang Maternal and Child Health Hospital and other teams. Director Liao Guilian of Longgang Maternal and Child Health Hospital raised the practical issues of clinical treatment of BPD and provided umbilical cord tissue and ideas for cell verification. Dr. Liao Yan’s team compared human umbilical cord mesenchymal stem cells (UC-MSC) cultured with hPL and FBS as culture medium additives respectively. font-family: inherit; vertical-align: baseline;”>The results show that the cell size, expansion ability, cell activity, anti-aging ability, anti-apoptosis ability, osteoblast and chondrocyte differentiation potential of UC-MSCs (hPL-UCMSCs) cultured with hPL are better than those of UC-MSCs cultured with FBS (FBS-UCMSCs); at the same time, the use of hPL increased the expression of the stemness gene Nestin in UCMSCs, and also greatly promoted the expression of various paracrine factors related to stem cells (VEGF, TGF-β1, FGF2, IL-8 and IL-6).

At the same time, in vivo experiments, the study constructed a newborn rat BPD model to evaluate its therapeutic effect. The results show thathPL-UCMSCs treatment can promote the development of small alveoli at the end of the bronchus. The number of small alveoli is significantly increased compared with the FBS-UCMSCs treatment group and the saline control group. Collagen deposition is significantly reduced, pulmonary fibrosis is significantly improved, the number of new blood vessels is significantly increased, macrophage infiltration is reduced, and the damaged lung condition is significantly improved; animal experimental results have confirmed that the therapeutic effect of hPL-UCMSCs is significantly better than that of FBS-UCMSCs.

The study proveshPL’s functional role as a supplement for UC-MSCs culture shows its important clinical value. This will help promote the widespread application of hPL in large-scale culture of UCMSCs in the future and provide more help for the clinical treatment of children with BPD.

Beike Biotechnology has been deeply engaged in the cell field for 16 years and has a top-notch mature stem cell scientific research team and cutting-edge cell storage and preparation technology. It has applied for 108 related patents in the biomedical field, 56 of which have been authorized; it has undertaken more than 60 national, provincial and municipal scientific research projects at all levels, including 863 projects, Torch Program projects, etc.; it has published 100+ papers related to the cell field, including 40+ SCI papers, with a cumulative impact factor (IF) of 200+.

References:

[1] Arrigoni et al, Cell, 2009; Willis et al, Am. J. Respir. Crit. Care Med, 2018

[2] Chang et al, Am. J. Respir. Cell Mol. Biol, 2014; Reiter et al, Respir. Res, 2017

[3] Trubiaietal et al,Part C Methods,2015